Guillain-Barre syndrome due to combination use of sunitinib and pembrolizumab

袁微,李运景,徐萍,刘文辉

DOI: https://doi.org/10.3760/cma.j.cn114015-20190305-00207

2020-01-01

Abstract:A 56-year-old male patient with recurrent renal cell carcinoma and splenic metastasis received oral sunitinib 50 mg/d (4 weeks of medication and 2 weeks of withdrawal were defined as 1 cycle; the dosage was reduced to 25 mg/d after 2 cycles). And intravenous infusion of pembrolizumab 100 mg once every 3 weeks was added because of his illness. After 3 cycles of sunitinib and 5 cycles of pembrolizumab treatments, the patient developed muscle and joint pain, joint swelling, movement disorder, abnormal limb sensation and gradually developed symptoms such as difficulty in defecation, choking of drinking water, dysphagia, and dyspnea. The patient was diagnosed as Guillain-Barre syndrome after neurologist consultation, which might be related to the combination use of sunitinib and pembrolizumab. The above 2 drugs were stopped and dexamethasone and human immunoglobulin (pH4) for intravenous injection were given. Three days later, the patient could turn over on his own; 5 days later, his symptoms of dysphagia, dyspnea, and muscle and joint pain were relieved; 10 days later, he could stand beside the bed; one and a half month later, he could walk independently.